Gland Pharma Q2 profit jumps 58.2% to ₹291 crore
In short
Gland Pharma reported strong Q2 FY27 results. Net profit rose 58.2% year on year to ₹291 crore, revenue increased 23.3% to ₹1,834 crore, and EBITDA jumped 54.1% to ₹484 crore.
The company also said CDMO revenue grew 31% and Critical Injectables revenue rose 18%, which points to solid business momentum.
What the reporting says
Gland Pharma reported a 58.2% year-on-year rise in Q2 FY27 net profit to ₹291 crore, while revenue increased 23.3% to ₹1,834 crore. EBITDA surged 54.1% to ₹484 crore and margins expanded to 26.4%. The company said CDMO revenue grew 31% and Critical Injectables revenue rose 18%, showing broad-based business growth in the quarter.
Why it matters
Gland Pharma posted a sharp rise in Q2 FY27 profit, supported by higher revenue and stronger operating performance. Net profit reached ₹291 crore, revenue came in at ₹1,834 crore, and EBITDA margins expanded to 26.4%. Growth in the CDMO business and Critical Injectables added to the positive quarter for the pharmaceutical company.